Expanded analyses of NAPOLI-1: phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Authors
Chen, LVon Hoff, D
Li, C
Wang-Gillam, A
Bodoky, G
Dean, A
Shan, Y
Jameson, G
Macarulla, T
Lee, K
Cunningham, D
Blanc, J
Hubner, Richard A
Chiu, C
Schwartsmann, G
Braiteh, F
Moyo, V
Belanger, B
Bayever, E
Issue Date
2016